Status: Not yet recruiting
EGEN-5784 Porcine Liver With the Metra® ELC Device
This is a Phase 1, first-in-human (FIH) safety, proof-of-concept, two-part study of the genetically-engineered EGEN-5784 liver in combination with the metra® extra-corporeal liver cross-circulation (ELC) system in participants with Grade 2 to Grade 3 acute-on-chronic liver failure (ACLF) and hepatic encephalopathy Grade 1-3. The metra® device has been modified for the purposes of cross-circulation with an extra-corporeal porcine liver. The EGEN-5784 liver and metra® ELC device are designed to support liver function during the treatment period
Participants needed: 20
Trial details
Phase: Phase 1Age: 18-70Biological sex: AllType: InterventionalSponsor: eGenesis, INCUpdated: May 7, 2026Locations: 2
Eligibility criteria
Male or female, age 18 to 70 years, inclusive [+4]
Prior solid organ transplant [+11]